Immunohistochemical, molecular, and clinicopathological analyses of urothelial carcinoma, micropapillary variant

Pathology International

Volumn 61, Issue 12, 2011, Pages 723-730

  Ishii, Shuhei ^a   Ohbu, Makoto ^b   Toomine, Yukie ^a   Nishimura, Yukari ^b   Hattori, Manabu ^b   Yokoyama, Masaru ^c   Toyonaga, Masumi ^c   Kakinuma, Hirokuni ^c   Matsumoto, Kazumasa ^b  

^a KITASATO UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b KITASATO UNIVERSITY   (Japan)

^c KITASATO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Bladder carcinoma; Fibronectin; KRAS; MUC1; Tenascin C; Urothelial carcinoma micropapillary variant

Indexed keywords

CD147 ANTIGEN; CD34 ANTIGEN; FIBRONECTIN; K RAS PROTEIN; KI 67 ANTIGEN; MONOCLONAL ANTIBODY D2-40; MUCIN 1; PROTEIN P53; TENASCIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; EPITHELIAL MESENCHYMAL TRANSITION; EXON; GENE MUTATION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TRANSITIONAL CELL CARCINOMA; TUMOR EMBOLISM;

AGED; CARCINOMA, PAPILLARY; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS P21(RAS); RAS PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 82455209018     PISSN: 13205463     EISSN: 14401827     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2011.02731.x     Document Type: Article

References (40)

1. Amin MB, Ro JY, El-Sharkawy T etal. Micropapillary variant of transitional cell carcinoma of the urinary bladder. Histologic pattern resembling ovarian papillary serous carcinoma. Am J Surg Pathol 1994; 18: 1224-32.
2. Lopez-Beltran A, Knowles MA, Sauter G etal. Infiltrating urothelail carcinoma. In: Eble JN, Sauter G, Ebstein JI, Sesterhenn IA, eds. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: IARC Press, 2004; 93-109.
3. Nassar H, Pansare V, Zhang H etal. Pathogenesis of invasive micropapillary carcinoma: Role of MUC1 glycoprotein. Mod Pathol 2004; 17: 1045-50.
4. De la Cruz C, Moriya T, Endoh M etal. Invasive micropapillary carcinoma of the breast: Clinicopathological and immunohistochemical study. Pathol Int 2004; 54: 90-6.
5. Miyoshi T, Shirakusa T, Ishikawa Y etal. Possible mechanism of metastasis in lung adenocarcinomas with a micropapillary pattern. Pathol Int 2005; 55: 419-24.
6. Sakamoto K, Watanabe M, De La Cruz C etal. Primary invasive micropapillary carcinoma of the colon. Histopathology 2005; 47: 479-84.
7. Nagao T, Gaffey TA, Visscher DW etal. Invasive micropapillary salivary duct carcinoma: A distinct histologic variant with biologic significance. Am J Surg Pathol 2004; 28: 319-26.
8. Johansson SL, Borghede G, Holmäng S. Micropapillary bladder carcinoma: A clinicopathological study of 20 cases. J Urol 1999; 161: 1798-802.
9. Sasaki M, Ikeda H, Nakanuma Y. Expression profiles of MUC mucins and trefoil factor family (TFF) peptides in the intrahepatic biliary system: Physiological distribution and pathological significance. Prog Histochem Cytochem 2007; 42: 61-110.
10. Margulis V, Shariat SF, Ashfaq R, Sagalowsky AI, Lotan Y. Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res 2006; 12: 7369-73.
11. Margulis V, Lotan Y, Karakiewicz PI etal. Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst 2009; 101: 114-9.
12. Seo HK, Cho KS, Chung J etal. Prognostic value of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer receiving adjuvant intravesical mitomycin C therapy. Urology 2010; 76: 512.e1-7.
13. Grossman HB, Tangen CM, Cordon-Cardo C etal. Evaluation of Ki67, p53 and angiogenesis in patients enrolled in a randomized study of neoadjuvant chemotherapy with or without cystectomy: A Southwest Oncology Group Study. Oncol Rep 2006; 16: 807-10.
14. Smith ND, Rubenstein JN, Eggener SE, Kozlowski JM. The p53 tumor suppressor gene and nuclear protein: Basic science review and relevance in the management of bladder cancer. J Urol 2003; 169: 1219-28.
15. Lipponen PK. Over-expression of p53 nuclear oncoprotein in transitional-cell bladder cancer and its prognostic value. Int J Cancer 1993; 53: 365-70.
16. Qureshi KN, Griffiths TR, Robinson MC etal. TP53 accumulation predicts improved survival in patients resistant to systemic cisplatin-based chemotherapy for muscle-invasive bladder cancer. Clin Cancer Res 1999; 5: 3500-7.
17. Sarkis AS, Bajorin DF, Reuter VE etal. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 1995; 13: 1384-90.
18. Tiguert R, Bianco FJ Jr, Oskanian P etal. Structural alteration of p53 protein in patients with muscle invasive bladder transitional cell carcinoma. J Urol 2001; 166: 2155-60.
19. Kuczyk MA, Bokemeyer C, Serth J etal. p53 overexpression as a prognostic factor for advanced stage bladder cancer. Eur J Cancer 1995; 31A: 2243-7.
20. Sienel W, Polzer B, Elshawi K etal. Cellular localization of EMMPRIN predicts prognosis of patients with operable lung adenocarcinoma independent from MMP-2 and MMP-9. Mod Pathol 2008; 21: 1130-8.
21. Ishibashi Y, Matsumoto T, Niwa M, Suzuki Y etal. CD147 and matrix metalloproteinase-2 protein expression as significant prognostic factors in esophageal squamous cell carcinoma. Cancer 2004; 101: 1994-2000.
22. Chung CY, Murphy-Ullrich JE, Erickson HP. Mitogenesis, cell migration, and loss of focal adhesions induced by tenascin-C interacting with its cell surface receptor, annexin II. Mol Biol Cell 1996; 7: 883-92.
23. Ghert MA, Qi WN, Erickson HP, Block JA, Scully SP. Tenascin-C splice variant adhesive/anti-adhesive effects on chondrosarcoma cell attachment to fibronectin. Cell Struct Funct 2001; 26: 179-87.
24. Phillips GR, Krushel LA, Crossin KL. Domains of tenascin involved in glioma migration. J Cell Sci 1998; 111: 1095-104.
25. Nagaharu K, Zhang X, Yoshida T etal. Tenascin C induces epithelial-mesenchymal transition-like change accompanied by Src activation and focal adhesion kinase phosphorylation in human breast cancer cells. Am J Pathol 2011; 178: 754-63.
26. Murphy-Ullrich JE, Lightner VA, Aukhil I, Yan YZ, Erickson HP, Hook M. Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin. J Cell Biol 1991; 115: 1127-36.
27. Cowan KN, Jones PL, Rabinovitch M. Elastase and matrix metalloproteinase inhibitors induce regression, and tenascin-C antisense prevents progression, of vascular disease. J Clin Invest 2000; 105: 21-34.
28. Schenk S, Chiquet-Ehrismann R, Battegay EJ. The fibrinogen globe of tenascin-C promotes basic fibroblast growth factor-induced endothelial cell elongation. Mol Biol Cell 1999; 10: 2933-43.
29. Tremble P, Chiquet-Ehrismann R, Werb Z. The extracellular matrix ligands fibronectin and tenascin collaborate in regulating collagenase gene expression in fibroblasts. Mol Biol Cell 1994; 5: 439-53.
30. Sternlicht MD, Lochter A, Sympson CJ etal. The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis. Cell 1999; 98: 137-46.
31. Huang W, Chiquet-Ehrismann R, Moyano JV, Garcia-Pardo A, Orend G. Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation. Cancer Res 2001; 61: 8586-94.
32. Woods A, Longley RL, Tumova S, Couchman JR. Syndecan-4 binding to the high affinity heparin-binding domain of fibronectin drives focal adhesion formation in fibroblasts. Arch Biochem Biophys 2000; 374: 66-72.
33. Elenius K, Jalkanen M. Function of the syndecans-a family of cell surface proteoglycans. J Cell Sci 1994; 107: 2975-82. Review.
34. Carter WG, Wayner EA, Bouchard TS, Kaur P. The role of integrins alpha 2 beta 1 and alpha 3 beta 1 in cell-cell and cell-substrate adhesion of human epidermal cells. J Cell Biol 1990; 110: 1387-404.
35. Bass MD. The role of structural extracellular matrix proteins in urothelial bladder cancer. Biomark Insights 2007; 2: 418-27.
36. Mitra AK, Sawada K, Tiwari P, Mui K, Gwin K, Lengyel E. Ligand-independent activation of c-Met by fibronectin and α(5)β(1)-integrin regulates ovarian cancer invasion and metastasis. Oncogene 2011; 30: 1566-76.
37. Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS ONE 2010; 5: e13821.
38. Latif Z, Watters AD, Dunn I, Grigor K, Underwood MA, Bartlett JM. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: A role for anti-HER2 therapy? Eur J Cancer 2004; 40: 56-63.
39. Karimianpour N, Mousavi-Shafaei P, Ziaee AA etal. Mutations of RAS gene family in specimens of bladder cancer. Urol J 2008; 5: 237-42.
40. Lopez-Beltran A, Montironi R, Blanca A, Cheng L. Invasive micropapillary urothelial carcinoma of the bladder. Hum Pathol 2010; 41: 1159-64.